Myxobacterium-produced antibiotic TA (myxovirescin) inhibits type II signal peptidase

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 4, 2012, Pages 2014-2021

  Xiao, Yao ^a   Gerth, Klaus ^b   Müller, Rolf ^b   Wall, Daniel ^a  

^a UNIVERSITY OF WYOMING   (United States)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; BACITRACIN; CHLORAMPHENICOL; GLOBOMYCIN; LIPOPROTEIN; MYXOVIRESCIN; POLYMYXIN B; RIFAMPICIN; SIGNAL PEPTIDASE II; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENETICS; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; CELL ADHESION; CELL GROWTH; CELL MEMBRANE; CELL METABOLISM; CELL STRUCTURE; CELL WALL; CONTROLLED STUDY; ENZYME INHIBITION; ESCHERICHIA COLI; GENE INSERTION; MISSENSE MUTATION; MOLECULAR CLONING; MYXOCOCCALES; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS;

ANTI-BACTERIAL AGENTS; ASPARTIC ACID ENDOPEPTIDASES; BACTERIAL PROTEINS; CHROMOSOME MAPPING; CHROMOSOMES, BACTERIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; MACROLIDES; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, FLUORESCENCE; MUTAGENESIS; MYXOCOCCUS XANTHUS; PEPTIDES; PLASMIDS; PROTEASE INHIBITORS; PROTEIN BIOSYNTHESIS;

EID: 84858650670     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06148-11     Document Type: Article

References (52)

1. Calderone CT, Iwig DF, Dorrestein PC, Kelleher NL, Walsh CT. 2007. Incorporation of nonmethyl branches by isoprenoid-like logic: multiple beta-alkylation events in the biosynthesis of myxovirescin A1. Chem. Biol. 14:835-846. (Pubitemid 47081426)
2. Chimalakonda G, et al. 2011. Lipoprotein LptE is required for the assembly of LptD by the beta-barrel assembly machine in the outer membrane of Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 108:2492-2497.
3. Content S, Dutton CJ, Roberts L. 2003. Myxovirescin analogues via macrocyclic ring-closing metathesis. Bioorg. Med. Chem. Lett. 13:321-325. (Pubitemid 36259683)
4. Eli I, Judes H, Varon M, Manor A, Rosenberg E. 1988. Antibiotic TA - a new adherent agent for the treatment of periodontal disease. Refuat Hashinayim 6:14-15.
5. Froelich JM, Tran K, Wall D. 2006. A pmrA constitutive mutant sensitizes Escherichia coli to deoxycholic acid. J. Bacteriol. 188:1180-1183. (Pubitemid 43146436)
6. Gerth K, Irschik H, Reichenbach H, Trowitzsch W. 1982. The myxovirescins, a family of antibiotics from Myxococcus virescens (Myxobacterales). J. Antibiot. (Tokyo) 35:1454-1459. (Pubitemid 13217757)
7. Goldman BS, et al. 2006. Evolution of sensory complexity recorded in a myxobacterial genome. Proc. Natl. Acad. Sci. U. S. A. 103:15200-15205. (Pubitemid 44583188)
8. Hayashi S, Wu HC. 1990. Lipoproteins in bacteria. J. Bioenerg. Biomembr. 22:451-471. (Pubitemid 20192845)
9. Hussain M, Ichihara S, Mizushima S. 1980. Accumulation of glyceridecontaining precursor of the outer membrane lipoprotein in the cytoplasmic membrane of Escherichia coli treated with globomycin. J. Biol. Chem. 255:3707-3712. (Pubitemid 10011834)
10. Hutchings MI, Palmer T, Harrington DJ, Sutcliffe IC. 2009. Lipoprotein biogenesis in Gram-positive bacteria: knowing when to hold 'em, knowing when to fold 'em. Trends Microbiol. 17:13-21.
11. Inukai M, Takeuchi M, Shimizu K. 1984. Effects of globomycin on the morphology of bacteria and the isolation of resistant mutants. Agric. Biol. Chem. 48:513-518.
12. Kitagawa M, et al. 2005. Complete set of ORF clones of Escherichia coli ASKA library (a complete set of E. coli K-12 ORF archive): unique resources for biological research. DNA Res. 12:291-299.
13. Krug D, et al. 2008. Discovering the hidden secondary metabolome of Myxococcus xanthus: a study of intraspecific diversity. Appl. Environ. Microbiol. 74:3058-3068. (Pubitemid 351747010)
14. Lai JS, et al. 1981. Globomycin sensitivity of Escherichia coli and Salmonella typhimurium: effects of mutations affecting structures of murein lipoprotein. J. Bacteriol. 145:657-660. (Pubitemid 11187937)
15. Manor A, Eli I, Varon M, Judes H, Rosenberg E. 1989. Effect of adhesive antibiotic TA on plaque and gingivitis in man. J. Clin. Periodontol. 16:621-624. (Pubitemid 19277927)
16. Miller JH. 1992. A short course in bacterial genetics: a laboratory manual and handbook for Escherichia coli and related bacteria. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
17. Miyashiro S, Yamanaka S, Takayama S, Shibai H. 1988. Novel macrocyclic antibiotics: megovalicins A, B, C, D, G and H. I. Screening of antibiotics- producing myxobacteria and production of megovalicins. J. Antibiot. (Tokyo) 41:433-438.
18. Munoa FJ, Miller KW, Beers R, Graham M, Wu HC. 1991. Membrane topology of Escherichia coli prolipoprotein signal peptidase (signal peptidase II). J. Biol. Chem. 266:17667-17672. (Pubitemid 21907989)
19. Ni Y, Reye J, Chen RR. 2007. lpp deletion as a permeabilization method. Biotechnol. Bioeng. 97:1347-1356. (Pubitemid 47204013)
20. Nichols BP, Shafiq O, Meiners V. 1998. Sequence analysis of Tn10 insertion sites in a collection of Escherichia coli strains used for genetic mapping and strain construction. J. Bacteriol. 180:6408-6411. (Pubitemid 28544278)
21. Onishi N, Izaki K, Takahashi H. 1984. A macrocyclic antibiotic M-230B produced by Myxococcus xanthus. Isolation and characterization. J. Antibiot. (Tokyo) 37:13-19. (Pubitemid 14180555)
22. Paitan Y, Alon G, Orr E, Ron EZ, Rosenberg E. 1999. The first gene in the biosynthesis of the polyketide antibiotic TA of Myxococcus xanthus codes for a unique PKS module coupled to a peptide synthetase. J. Mol. Biol. 286:465-474. (Pubitemid 29090163)
23. Paitan Y, Orr E, Ron EZ, Rosenberg E. 1999. A nonessential signal peptidase II (Lsp) of Myxococcus xanthus might be involved in biosynthesis of the polyketide antibiotic TA. J. Bacteriol. 181:5644-5651. (Pubitemid 29437134)
24. Paradis-Bleau C, et al. 2010. Lipoprotein cofactors located in the outer membrane activate bacterial cell wall polymerases. Cell 143:1110-1120.
25. Reichenbach H, Höfle G. 1993. Biologically active secondary metabolites from myxobacteria. Biotechnol. Adv. 11:219-277. (Pubitemid 23679499)
26. Rosenberg E, Dworkin M. 1996. Autocides and a paracide, antibiotic TA, produced by Myxococcus xanthus. J. Ind. Microbiol. 17:424-431.
27. Rosenberg E, Porter JM, Nathan PN, Manor A, Varon M. 1984. Antibiotic TA: an adherent antibiotic. Nat. Biotechnol. 2:796-799. (Pubitemid 15083435)
28. Rosenberg E, Vaks B, Zuckerberg A. 1973. Bactericidal action of an antibiotic produced by Myxococcus xanthus. Antimicrob. Agents Chemother. 4:507-513.
29. Sambrook J, Russell DW. 2001. Molecular cloning: a laboratory manual, 3rd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
30. Sampson BA, Misra R, Benson SA. 1989. Identification and characterization of a new gene of Escherichia coli K-12 involved in outer membrane permeability. Genetics 122:491-501.
31. Schierholz JM, Beuth J. 2001. Implant infections: a haven for opportunistic bacteria. J. Hosp. Infect. 49:87-93. (Pubitemid 32982681)
32. Simhi E, van der Mei HC, Ron EZ, Rosenberg E, Busscher HJ. 2000. Effect of the adhesive antibiotic TA on adhesion and initial growth of E. coli on silicone rubber. FEMS Microbiol. Lett. 192:97-100.
33. Simunovic V, Müller R. 2007. 3-Hydroxy-3-methylglutaryl-CoA-like synthases direct the formation of methyl and ethyl side groups in the biosynthesis of the antibiotic myxovirescin A. Chembiochem 8:497-500. (Pubitemid 47183645)
34. Simunovic V, Müller R. 2007. Mutational analysis of the myxovirescin biosynthetic gene cluster reveals novel insights into the functional elaboration of polyketide backbones. Chembiochem 8:1273-1280. (Pubitemid 47171994)
35. Simunovic V, et al. 2006. Myxovirescin A biosynthesis is directed by hybrid polyketide synthases/nonribosomal peptide synthetase, 3-hydroxy-3-methylglutaryl-CoA synthases, and trans-acting acyltransferases. Chembiochem 7:1206-1220. (Pubitemid 44230844)
36. Talbot GH, et al. 2006. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 42:657-668. (Pubitemid 43271379)
37. Tjalsma H, et al. 1999. The role of lipoprotein processing by signal peptidase II in the Gram-positive eubacterium Bacillus subtilis. Signal peptidase II is required for the efficient secretion of alpha-amylase, a nonlipoprotein. J. Biol. Chem. 274:1698-1707.
38. Tjalsma H, Zanen G, Venema G, Bron S, van Dijl JM. 1999. The potential active site of the lipoprotein-specific (type II) signal peptidase of Bacillus subtilis. J. Biol. Chem. 274:28191-28197.
39. Tokuda H, Matsuyama S. 2004. Sorting of lipoproteins to the outer membrane in E. coli. Biochim. Biophys. Acta 1694:IN1-9.
40. Tokunaga M, Loranger JM, Wu HC. 1983. Isolation and characterization of an Escherichia coli clone overproducing prolipoprotein signal peptidase. J. Biol. Chem. 258:12102-12105.
41. Typas A, et al. 2010. Regulation of peptidoglycan synthesis by outermembrane proteins. Cell 143:1097-1109.
42. Wei X, Pathak DT, Wall D. 2011. Heterologous protein transfer within structured myxobacteria biofilms. Mol. Microbiol. 81:315-326.
43. Weissman KJ, Müller R. 2009. A brief tour of myxobacterial secondary metabolism. Bioorg. Med. Chem. 17:2121-2136.
44. Wenzel SC, Müller R. 2009. Myxobacteria - 'microbial factories' for the production of bioactive secondary metabolites. Mol. Biosyst. 5:567-574.
45. Williams D, Li J. 1990. Total synthesis of myxovirescin B. J. Org. Chem. 55:3457-3459. (Pubitemid 20282022)
46. Wu HC. 1996. Biosynthesis of lipoproteins, p 1005-1014. In Neidhardt FC, et al. (ed), Escherichia coli and Salmonella: cellular and molecular biology, 2nd ed, vol 1. ASM Press, Washington, DC.
47. Xiao Y, Wei X, Ebright R, Wall D. 2011. Antibiotic production by myxobacteria plays a role in predation. J. Bacteriol. 193:4626-4633.
48. Xu HH, et al. 2010. Staphylococcus aureus TargetArray: comprehensive differential essential gene expression as a mechanistic tool to profile antibacterials. Antimicrob. Agents Chemother. 54:3659-3670.
49. Yakushi T, Tajima T, Matsuyama S, Tokuda H. 1997. Lethality of the covalent linkage between mislocalized major outer membrane lipoprotein and the peptidoglycan of Escherichia coli. J. Bacteriol. 179:2857-2862. (Pubitemid 27194431)
50. Yamagata H, Ippolito C, Inukai M, Inouye M. 1982. Temperaturesensitive processing of outer membrane lipoprotein in an Escherichia coli mutant. J. Bacteriol. 152:1163-1168. (Pubitemid 13190422)
51. Zafriri D, Rosenberg E, Mirelman D. 1981. Mode of action of Myxococcus xanthus antibiotic TA. Antimicrob. Agents Chemother. 19:349-351. (Pubitemid 11157529)
52. Zhou Y, et al. 2005. Structure-guided discovery of novel aminoglycoside mimetics as antibacterial translation inhibitors. Antimicrob. Agents Chemother. 49:4942-4949. (Pubitemid 41778904)